All In Biotech

Drug Trial Radar · NCT03700242

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular Post-Exposure Prophylaxis Regimen at One Year

Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

570

Actual

Start

Sep 26, 2018

Primary completion

Jan 19, 2019

Study completion Apr 8, 2020

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate. The secondary objectives of the study are: * To describe the immunogenicity of the PrEP regimen in each group * To describe the antibody persistence in each group 6 months and 1 year after the last PrEP vaccination * To describe the immunogenicity of the simulated post-exposure prophylaxis (PEP) regimen in each group * To describe the safety profile of study vaccines administered as PrEP regimen and as a simulated PEP regimen in each group

Conditions

  • Healthy Volunteers (Rabies Immunization)

Interventions

  • HDCVBiological

    Pharmaceutical form:Solution for injection Route of administration: Intramuscular

  • HDCVBiological

    Pharmaceutical form:Solution for injection Route of administration: Intradermal

  • PVRVBiological

    Pharmaceutical form:Solution for injection Route of administration: Intramuscular

  • PVRVBiological

    Pharmaceutical form:Solution for injection Route of administration: Intradermal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion of participantTime frame: 14 days after the last PrEP vaccination

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 002

    Cebu City, Philippines

  • Investigational Site Number 001

    City of Muntinlupa, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.